Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Exp Neurol. 2021 Aug 25;346:113838. doi: 10.1016/j.expneurol.2021.113838

Fig. 4: Contribution of CaV3.2 to diabetes-induced changes in stimulated CGRP release.

Fig. 4:

A. KCl-evoked CGRP release from skin of healthy and diabeticCaV3.2 KO mice. B. KCl-evoked CGRP release from sciatic nerve of healthy and diabetic CaV3.2 KO mice. C. KCl-evoked CGRP release from skin of diabetic C57BL/6J and effect of the CaV3.2 blocker TTA-P2 . D. KCl-evoked CGRP release from sciatic nerve of diabetic C57BL/6J and no effect of the CaV3.2 blocker TTA-P2. Significant increases in CGRP release over baseline and significant differences between experimental groups are marked with a hashtag an asterisk based on Wilcoxon matched pairs test and ANOVA repeated measurements, respectively.